FDA approves Kalydeco to treat rare form of cystic fibrosis

The FDA has approved the drug Kalydeco to be used towards the treatment of a rare form of cystic fibrosis in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator gene.

Read the full announcement here